Recurrent cervical cancer treated with cisplatin and methotrexate.
dc.contributor.author | Obasaju, Coleman K | |
dc.contributor.author | Cowan, Richard A | |
dc.contributor.author | Wilkinson, Peter M | |
dc.date.accessioned | 2010-05-25T11:05:08Z | |
dc.date.available | 2010-05-25T11:05:08Z | |
dc.date.issued | 1993 | |
dc.identifier.citation | Recurrent cervical cancer treated with cisplatin and methotrexate. 1993, 5 (4):203-6 Clin Oncol | en |
dc.identifier.issn | 0936-6555 | |
dc.identifier.pmid | 8398915 | |
dc.identifier.doi | 10.1016/S0936-6555(05)80228-6 | |
dc.identifier.uri | http://hdl.handle.net/10541/99798 | |
dc.description.abstract | A combination of cisplatin (80 mg/m2) and methotrexate (200 mg bolus and 400 mg as a 12-hour infusion) was given to 40 patients who developed local recurrence of cervical cancer after radiotherapy. A maximum of six courses was given at monthly intervals. Twenty-five of the forty (63%) evaluable patients responded, of which 4 (10%) responded completely. A symptomatic response, with reduction of pain, leg oedema, vaginal discharge and breathlessness was seen in 27 (68%) of patients. The median survival of all patients was 11 months. Toxicity was moderate; WHO grade 1 or greater was observed in 83% for nausea and vomiting, 67% for myelosuppression and 47% for mucositis. This combination chemotherapy is active in the treatment of recurrent cervical cancer and a modification of this regimen is currently being assessed as neo-adjuvant therapy in patients with Stage IIB-IVA cervical cancer. | |
dc.language.iso | en | en |
dc.subject | Cancer Recurrence | en |
dc.subject.mesh | Adenocarcinoma | |
dc.subject.mesh | Adult | |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject.mesh | Carcinoma, Adenosquamous | |
dc.subject.mesh | Carcinoma, Squamous Cell | |
dc.subject.mesh | Chemotherapy, Adjuvant | |
dc.subject.mesh | Cisplatin | |
dc.subject.mesh | Drug Administration Schedule | |
dc.subject.mesh | Female | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Methotrexate | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Neoplasm Recurrence, Local | |
dc.subject.mesh | Survival Rate | |
dc.subject.mesh | Uterine Cervical Neoplasms | |
dc.title | Recurrent cervical cancer treated with cisplatin and methotrexate. | en |
dc.type | Article | en |
dc.contributor.department | Christie Hospital NHS Trust, Withington, Manchester, UK. | en |
dc.identifier.journal | Clinical Oncology | en |
html.description.abstract | A combination of cisplatin (80 mg/m2) and methotrexate (200 mg bolus and 400 mg as a 12-hour infusion) was given to 40 patients who developed local recurrence of cervical cancer after radiotherapy. A maximum of six courses was given at monthly intervals. Twenty-five of the forty (63%) evaluable patients responded, of which 4 (10%) responded completely. A symptomatic response, with reduction of pain, leg oedema, vaginal discharge and breathlessness was seen in 27 (68%) of patients. The median survival of all patients was 11 months. Toxicity was moderate; WHO grade 1 or greater was observed in 83% for nausea and vomiting, 67% for myelosuppression and 47% for mucositis. This combination chemotherapy is active in the treatment of recurrent cervical cancer and a modification of this regimen is currently being assessed as neo-adjuvant therapy in patients with Stage IIB-IVA cervical cancer. |